Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.48 |
| ▸ | RAB9A | P51151 | 3/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | ROCK2 | O75116 | 5/20 | 0.45 |
| ▸ | ROCK1 | Q13464 | 5/20 | 0.45 |
| ▸ | PYGL | P06737 | 3/20 | 0.45 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | EZH2 | Q15910 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 5/20 | 0.42 |
| ▸ | PPARG | P37231 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14587741 | 0.90 | NPC1 (0.46) | NPC1RAB9AMAPTROCK2ROCK1 | |
| SCHEMBL5012144 | 0.90 | PPARG (0.52) | NPC1RAB9AMAPTNTRK1HPGD | |
| SCHEMBL5013605 | 0.89 | NPC1 (0.45) | NPC1RAB9AMAPTROCK2ROCK1 | |
| SCHEMBL5013482 | 0.89 | PPARG (0.44) | NPC1RAB9AROCK2ROCK1PYGL | |
| SCHEMBL5010360 | 0.88 | PPARG (0.43) | NPC1RAB9AROCK2ROCK1PYGL | |
| SCHEMBL5012281 | 0.87 | PPARG (0.47) | NPC1RAB9AMAPTNTRK1ALDH1A1 | |
| SCHEMBL5012109 | 0.86 | P2RX7 (0.47) | NPC1RAB9AROCK2ROCK1HPGD | |
| SCHEMBL5010595 | 0.86 | LMNA (0.50) | NPC1RAB9AMAPTPYGLSMN1; SMN2 | |
| SCHEMBL5010592 | 0.85 | MAPT (0.51) | RAB9AMAPTROCK2ROCK1HPGD | |
| SCHEMBL14587689 | 0.84 | NPC1 (0.46) | NPC1RAB9AMAPTROCK2ROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1884513-A1 | PYRAZOLE COMPOUND AND THERAPEUTIC AGENT FOR DIABETES COMPRISING THE SAME | Japan Tobacco, Inc. (JP) | 2008-02-06 | — | — | EP | claimed |
| US-20070032529-A1 | Pyrazole compounds and their use as antidiabetes agents | JAPAN TOBACCO INC. (JP) | 2007-02-08 | — | — | US | claimed |
| EP-1884513-A1 | PYRAZOLE COMPOUND AND THERAPEUTIC AGENT FOR DIABETES COMPRISING THE SAME | Japan Tobacco, Inc. (JP) | 2008-02-06 | — | — | EP | disclosed |
| US-20070032529-A1 | Pyrazole compounds and their use as antidiabetes agents | JAPAN TOBACCO INC. (JP) | 2007-02-08 | — | — | US | disclosed |
| US-20070032529-A1 | Pyrazole compounds and their use as antidiabetes agents | JAPAN TOBACCO INC. (JP) | 2007-02-08 | — | — | US | disclosed |
| US-20070032529-A1 | Pyrazole compounds and their use as antidiabetes agents | JAPAN TOBACCO INC. (JP) | 2007-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032529-A1 | Pyrazole compounds and their use as antidiabetes agents | PYGL, GYS2, AGL | NPC1 2838/4885RAB9A 2748/4885MAPT 4621/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.